NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns
This article was originally published in RPM Report
Executive Summary
Legislators are urging the National Institutes of Health to use intellectual property levers to put pressure on prescription drug pricing. NIH has historically been reluctant to play the role of the price police – and it still is.
You may also be interested in...
White House Science Advisor Shuffle Could Affect ARPA-H – And ‘March In’ Debate
Former NIH Director Francis Collins is returning to government as the top scientific advisor to President Biden. The post is temporary but comes at a critical time for the attempt to launch a new health innovation agency – and maybe for the direction of administrative pricing actions.
Xtandi Petition Will Give Biden Administration Chance To Weigh In On Pricing, March-In Rights
Prostate cancer patients press HHS for administrative hearing on march-in rights for patents covering Astellas’ Xtandi. While previous efforts have failed, petitioners believe they may have a shot this time around given Biden Administration and HHS Secretary Becerra’s views on the issue.
US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.